Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1984 1
1986 1
1988 3
1989 3
1990 4
1991 5
1992 2
1993 6
1994 9
1995 10
1996 7
1997 11
1998 11
1999 7
2000 16
2001 13
2002 16
2003 11
2004 7
2005 6
2006 10
2007 7
2008 13
2009 14
2010 13
2011 12
2012 8
2013 8
2014 13
2015 15
2016 13
2017 16
2018 14
2019 11
2020 7
2021 16
2022 18
2023 17
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

338 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "T-cell childhood lymphoblastic lymphoma"
Page 1
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.
Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, Qayed M, De Moerloose B, Hiramatsu H, Schlis K, Davis KL, Martin PL, Nemecek ER, Yanik GA, Peters C, Baruchel A, Boissel N, Mechinaud F, Balduzzi A, Krueger J, June CH, Levine BL, Wood P, Taran T, Leung M, Mueller KT, Zhang Y, Sen K, Lebwohl D, Pulsipher MA, Grupp SA. Maude SL, et al. N Engl J Med. 2018 Feb 1;378(5):439-448. doi: 10.1056/NEJMoa1709866. N Engl J Med. 2018. PMID: 29385370 Free PMC article. Clinical Trial.
BACKGROUND: In a single-center phase 1-2a study, the anti-CD19 chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel produced high rates of complete remission and was associated with serious but mainly reversible toxic effects in children and young adults …
BACKGROUND: In a single-center phase 1-2a study, the anti-CD19 chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel …
Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children's Oncology Group AALL0434.
Hayashi RJ, Winter SS, Dunsmore KP, Devidas M, Chen Z, Wood BL, Hermiston ML, Teachey DT, Perkins SL, Miles RR, Raetz EA, Loh ML, Winick NJ, Carroll WL, Hunger SP, Lim MS, Gross TG, Bollard CM. Hayashi RJ, et al. J Clin Oncol. 2020 Sep 10;38(26):3062-3070. doi: 10.1200/JCO.20.00531. Epub 2020 Jun 17. J Clin Oncol. 2020. PMID: 32552472 Free PMC article. Clinical Trial.
PURPOSE: The Children's Oncology Group (COG) protocol AALL0434 evaluated the safety and efficacy of multi-agent chemotherapy with Capizzi-based methotrexate/pegaspargase (C-MTX) in patients with newly diagnosed pediatric T-cell lymphoblastic lymphoma ( …
PURPOSE: The Children's Oncology Group (COG) protocol AALL0434 evaluated the safety and efficacy of multi-agent chemotherapy with Capizzi-ba …
Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children's Oncology Group study.
Wood BL, Devidas M, Summers RJ, Chen Z, Asselin B, Rabin KR, Zweidler-McKay PA, Winick NJ, Borowitz MJ, Carroll WL, Raetz EA, Loh ML, Hunger SP, Dunsmore KP, Teachey DT, Winter SS. Wood BL, et al. Blood. 2023 Dec 14;142(24):2069-2078. doi: 10.1182/blood.2023020678. Blood. 2023. PMID: 37556734 Clinical Trial.
The early thymic precursor (ETP) immunophenotype was previously reported to confer poor outcome in T-cell acute lymphoblastic leukemia (T-ALL). ...For subjects with day-29 MRD 1%, end-consolidation MRD 0.01% was a striking predictor of inferior …
The early thymic precursor (ETP) immunophenotype was previously reported to confer poor outcome in T-cell acute lymp …
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults.
Gardner RA, Finney O, Annesley C, Brakke H, Summers C, Leger K, Bleakley M, Brown C, Mgebroff S, Kelly-Spratt KS, Hoglund V, Lindgren C, Oron AP, Li D, Riddell SR, Park JR, Jensen MC. Gardner RA, et al. Blood. 2017 Jun 22;129(25):3322-3331. doi: 10.1182/blood-2017-02-769208. Epub 2017 Apr 13. Blood. 2017. PMID: 28408462 Free PMC article. Clinical Trial.
The MRD(-) remission rate was 93% in patients who received a CAR T-cell product and 100% in the subset of patients who received fludarabine and cyclophosphamide lymphodepletion. ...These data demonstrate that manufacturing a defined-composition CD19 CAR T …
The MRD(-) remission rate was 93% in patients who received a CAR T-cell product and 100% in the subset of patients who receive …
Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children's Oncology Group.
Horton TM, Whitlock JA, Lu X, O'Brien MM, Borowitz MJ, Devidas M, Raetz EA, Brown PA, Carroll WL, Hunger SP. Horton TM, et al. Br J Haematol. 2019 Jul;186(2):274-285. doi: 10.1111/bjh.15919. Epub 2019 Apr 7. Br J Haematol. 2019. PMID: 30957229 Free PMC article. Clinical Trial.
This phase 2 Children's Oncology Group study tested the hypothesis that adding the proteasome inhibitor bortezomib to chemotherapy increases complete response rates (CR2). Evaluable patients (n = 135, 103 B-ALL, 22 T-ALL, 10 T-lymphoblastic lymphoma) were treated wi …
This phase 2 Children's Oncology Group study tested the hypothesis that adding the proteasome inhibitor bortezomib to chemotherapy increases …
Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia.
Pulsipher MA, Han X, Maude SL, Laetsch TW, Qayed M, Rives S, Boyer MW, Hiramatsu H, Yanik GA, Driscoll T, Myers GD, Bader P, Baruchel A, Buechner J, Stefanski HE, Kalfoglou C, Nguyen K, Waldron ER, Thudium Mueller K, Maier HJ, Kari G, Grupp SA. Pulsipher MA, et al. Blood Cancer Discov. 2022 Jan;3(1):66-81. doi: 10.1158/2643-3230.BCD-21-0095. Epub 2021 Dec 1. Blood Cancer Discov. 2022. PMID: 35019853 Free PMC article.
We assessed minimal residual disease (MRD) detection and B-cell aplasia after tisagenlecleucel therapy for acute lymphoblastic leukemia (ALL) to define biomarkers predictive of relapse (N = 143). ...Relapses occurring with persistence of B-cell aplasia …
We assessed minimal residual disease (MRD) detection and B-cell aplasia after tisagenlecleucel therapy for acute lymphoblastic …
Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease.
Zuna J, Hovorkova L, Krotka J, Koehrmann A, Bardini M, Winkowska L, Fronkova E, Alten J, Koehler R, Eckert C, Brizzolara L, Trkova M, Stuchly J, Zimmermann M, De Lorenzo P, Valsecchi MG, Conter V, Stary J, Schrappe M, Biondi A, Trka J, Zaliova M, Cazzaniga G, Cario G. Zuna J, et al. Leukemia. 2022 Dec;36(12):2793-2801. doi: 10.1038/s41375-022-01668-0. Epub 2022 Aug 6. Leukemia. 2022. PMID: 35933523
Recently, we defined "CML-like" subtype of BCR::ABL1-positive acute lymphoblastic leukemia (ALL), resembling lymphoid blast crisis of chronic myeloid leukemia (CML). Here we retrospectively analyzed prognostic relevance of minimal residual disease (MRD) and other features …
Recently, we defined "CML-like" subtype of BCR::ABL1-positive acute lymphoblastic leukemia (ALL), resembling lymphoid blast crisis of …
Current and future role of bispecific T-cell engagers in pediatric acute lymphoblastic leukemia.
Algeri M, Del Bufalo F, Galaverna F, Locatelli F. Algeri M, et al. Expert Rev Hematol. 2018 Dec;11(12):945-956. doi: 10.1080/17474086.2018.1540928. Epub 2018 Nov 8. Expert Rev Hematol. 2018. PMID: 30358451 Review.
The clinical application of immunotherapy has resulted into a significant improvement in the outcome of children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (r/r BCP-ALL). In this setting, the use of bispecific T-cell- …
The clinical application of immunotherapy has resulted into a significant improvement in the outcome of children with relapsed/refractory B- …
Comprehensive Overview of Gene Rearrangements in Childhood T-Cell Acute Lymphoblastic Leukaemia.
Mroczek A, Zawitkowska J, Kowalczyk J, Lejman M. Mroczek A, et al. Int J Mol Sci. 2021 Jan 15;22(2):808. doi: 10.3390/ijms22020808. Int J Mol Sci. 2021. PMID: 33467425 Free PMC article. Review.
Acute lymphoblastic leukaemia (ALL) is a relevant form of childhood neoplasm, as it accounts for over 80% of all leukaemia cases. T-cell ALL constitutes a genetically heterogeneous cancer derived from T-lymphoid progenitors. ...
Acute lymphoblastic leukaemia (ALL) is a relevant form of childhood neoplasm, as it accounts for over 80% of all leukaemia cas …
Genomic and clinical characterization of early T-cell precursor lymphoblastic lymphoma.
Xu X, Paxton CN, Hayashi RJ, Dunsmore KP, Winter SS, Hunger SP, Winick NJ, Carroll WL, Loh ML, Devidas M, Gross TG, Bollard CM, Perkins SL, Miles RR. Xu X, et al. Blood Adv. 2021 Jul 27;5(14):2890-2900. doi: 10.1182/bloodadvances.2021004334. Blood Adv. 2021. PMID: 34297047 Free PMC article.
Early T-cell precursor phenotype acute lymphoblastic leukemia (ETP-ALL) is a subtype of T-ALL with a unique immunophenotype and genetic abnormalities distinct from conventional T-ALL. A subset of T lymphoblastic lymphoma (T-LLy) also demo …
Early T-cell precursor phenotype acute lymphoblastic leukemia (ETP-ALL) is a subtype of T-ALL with a unique immu …
338 results